
Cytek Biosciences, Inc. (($CTKB)) has held its Q3 earnings call. Read on for the main highlights of the call. Cytek Biosciences’ earnings call carried a generally positive tone, supported by
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| CTKB | Cytek Biosciences | 5.92 | 0.18 | 3.07% |
| Name | Price | % Change | |
|---|---|---|---|
| $5.92 | +3.07% |

Cytek Biosciences, Inc. (($CTKB)) has held its Q3 earnings call. Read on for the main highlights of the call. Cytek Biosciences’ earnings call carried a generally positive tone, supported by

Stephens raised the firm’s price target on Cytek Biosciences (CTKB) to $7 from $6 and keeps an Overweight rating on the shares after what the firm views as “a relatively

Stephens raised the firm’s price target on Cytek Biosciences (CTKB) to $6 from $4.75 and keeps an Overweight rating on the shares in conjunction with the firm’s Q3 earnings preview

Cytek Biosciences ( ($CTKB) ) has shared an announcement. On September 23, 2026, Cytek Biosciences, Inc.’s board unanimously adopted amended and restated bylaws that tighten requirements for shareholder proposals and

Sysmex Europe and Cytek Biosciences (CTKB) announced a strategic collaboration across over a dozen European countries to enhance clinical flow cytometry workflows and expand access to innovative diagnostic solutions. Published

Cytek Biosciences ( ($CTKB) ) has issued an announcement. On August 21, 2026, Cytek Biosciences reported that a Delaware federal jury returned a mixed verdict in a patent infringement case

Cytek Biosciences, Inc. (($CTKB)) has held its Q2 earnings call. Read on for the main highlights of the call. Cytek Biosciences’ latest earnings call painted a cautiously optimistic picture, balancing

Morgan Stanley lowered the firm’s price target on Cytek Biosciences (CTKB) to $5 from $5.50 and keeps an Equal Weight rating on the shares. Published first on TheFly – the

TD Cowen analyst Brendan Smith maintained a Hold rating on Cytek Biosciences yesterday and set a price target of $5.00. Brendan Smith has given his Hold rating due to a

Reports Q2 revenue $48.14M, consensus $48.61M. “Our second quarter results reflect continued execution against our strategic priorities, exemplified by strong double-digit revenue growth in instruments in the U.S. and in
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 4, 2027TBA | $745.47M | $0.01 | $63.38M | -0.01 | -9.02 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.